Surgical Procedure and Postoperative S-1 Chemotherapy Deliverability in Symptomatic Stage IV Gastric Cancer
In Vivo · 2026-11 · 40 (6) · 3704-3715
DOI: 10.21873/invivo.14509 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Kazuya Higashizono und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Shizuoka General Hospital, Shizuoka, Japan; sougou-soumu@shizuoka-pho.jp. Hauptthemen laut MEDLINE: Stomach Neoplasms, Tegafur, Oxonic Acid. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND/AIM: Symptomatic incurable stage IV gastric cancer (GC) may require palliative surgery for bleeding or obstruction before systemic therapy. We examined whether procedure type-distal gastrectomy (DG), total gastrectomy (TG), or gastrojejunostomy (GJ)-is associated with nutritional/inflammatory changes, S-1 deliverability, and overall survival (OS). PATIENTS AND METHODS: We retrospectively studied 49 patients who underwent palliative DG (n=13), TG (n=20), or GJ (n=16) and then received S-1 as first-line postoperative chemotherapy. Body weight, prognostic nutritional index (PNI), and neutrophil-to-lymphocyte ratio (NLR) were assessed preoperatively and before chemotherapy. Deliverability was evaluated by time to S-1 initiation, continuation beyond 3 months, and treatment modification within 3 months. OS was analyzed using Kaplan-Meier and Cox models. RESULTS: Postoperative complications were more frequent after GJ (p=0.002); time to S-1 initiation was similar among groups (p=0.144). S-1 continuation beyond 3 months was achieved in 29/49 patients (59.2%; DG 76.9%, TG 55.0%, GJ 50.0%; p=0.302). Weight loss was significantly greater after TG than after DG or GJ, and GJ showed a postoperative decline in PNI and a significantly higher pre-chemotherapy NLR than DG and TG (p=0.015 and p=0.036, respectively). Median OS was 474 days (DG: 812, TG: 422, and GJ: 293 days) and was significantly longer after DG than after TG (p=0.042) or GJ (p=0.003). In multivariate Cox analysis, chemotherapy for ≥3 months (HR=0.46, 95% CI=0.22-0.95; p=0.036) and high PNI (HR=0.31, 95% CI=0.13-0.77; p=0.012) were independent prognostic factors. CONCLUSION: In symptomatic incurable stage IV GC treated with palliative surgery followed by S-1, procedure type was associated with distinct perioperative profiles and OS. Maintaining chemotherapy and immuno-nutritional status may be clinically relevant in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Shizuoka General Hospital, Shizuoka, Japan; sougou-soumu@shizuoka-pho.jp.
- Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Gastroenterological Surgery, Shizuoka General Hospital, Shizuoka, Japan.
- Research Support Center, Shizuoka General Hospital, Shizuoka, Japan.
Zitieren
APA
Higashizono, K., Watanabe, M., Nagai, E., Taki, Y., Nishida, M., Sato, S., Nakatani, E., Baba, Y., & Kanemoto, H. (2026). Surgical Procedure and Postoperative S-1 Chemotherapy Deliverability in Symptomatic Stage IV Gastric Cancer. In Vivo, 40(6), 3704-3715. https://doi.org/10.21873/invivo.14509
Vancouver
Higashizono K, Watanabe M, Nagai E, Taki Y, Nishida M, Sato S, et al. Surgical Procedure and Postoperative S-1 Chemotherapy Deliverability in Symptomatic Stage IV Gastric Cancer. In Vivo. 2026;40(6):3704-3715. doi:10.21873/invivo.14509
BibTeX
@article{Higashizono2026,
author = {Higashizono, Kazuya and Watanabe, Masaya and Nagai, Erina and Taki, Yusuke and Nishida, Masato and Sato, Shinsuke and Nakatani, Eiji and Baba, Yoshifumi and Kanemoto, Hideyuki},
title = {Surgical Procedure and Postoperative S-1 Chemotherapy Deliverability in Symptomatic Stage IV Gastric Cancer},
journal = {In Vivo},
year = {2026},
volume = {40},
number = {6},
pages = {3704--3715},
doi = {10.21873/invivo.14509}
}
EUVIMED